Welcome

Pfenex is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins. Our initial focus is on biosimilar therapeutics and our lead product is PF582, a biosimilar to Lucentis ranibizumab. Our patented protein production platform, Pfenex Expression Technology. Pfenex is leveraging its technology platform for its own product pipeline. And for scientists seeking reagents for research use. Aug 17, 2015. Aug 13, 2015. Jul 29, 2015. Aug 17, 2015.

OVERVIEW

This web page pfenex.investorroom.com presently has a traffic classification of zero (the smaller the more users). We have scanned twelve pages inside the web site pfenex.investorroom.com and found thirty-nine websites referencing pfenex.investorroom.com. I acquired three public network sites belong to this website.
Pages Crawled
12
Links to this site
39
Social Links
3

PFENEX.INVESTORROOM.COM RANKINGS

This web page pfenex.investorroom.com is seeing variant quantities of traffic throughout the the year.
Traffic for pfenex.investorroom.com

Date Range

1 week
1 month
3 months
This Year
Last Year
All time
Traffic ranking (by month) for pfenex.investorroom.com

Date Range

All time
This Year
Last Year
Traffic ranking by day of the week for pfenex.investorroom.com

Date Range

All time
This Year
Last Year
Last Month

LINKS TO WEB SITE

Home Pfenex Innovative solutions for global health

We are a clinical stage development and licensing biotechnology company focused on leveraging our. Pfenex Expression Technology platform to develop and improve protein therapies for unmet patient needs. Learn about Pfenex Expression Technology and our other state of the art production capabilities. Learn about our advanced pipeline of therapeutic equivalents, vaccines, biologics, and biosimilars.

Pfenex Innovative solutions for global health through biosimilars.

We are an innovative, leading-edge company focused on bringing biosimilars to market. Learn more about our approach to biosimilars. Our analytical approach to biosimilars allows us to provide patients access to safe, effective, and affordable products. Learn how this supports our robust product pipeline. Our innovative technology and ability to rapidly create a stockpile of essential vaccines has positioned us as a primary partner with the US Government.

WHAT DOES PFENEX.INVESTORROOM.COM LOOK LIKE?

Desktop Screenshot of pfenex.investorroom.com Mobile Screenshot of pfenex.investorroom.com Tablet Screenshot of pfenex.investorroom.com

PFENEX.INVESTORROOM.COM HOST

I revealed that the main root page on pfenex.investorroom.com took six thousand five hundred and sixteen milliseconds to download. We could not detect a SSL certificate, so therefore our parsers consider this site not secure.
Load time
6.516 secs
SSL
NOT SECURE
Internet Protocol
64.78.159.10

BROWSER ICON

SERVER OS AND ENCODING

I caught that pfenex.investorroom.com is implementing the Apache operating system.

PAGE TITLE

Welcome

DESCRIPTION

Pfenex is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins. Our initial focus is on biosimilar therapeutics and our lead product is PF582, a biosimilar to Lucentis ranibizumab. Our patented protein production platform, Pfenex Expression Technology. Pfenex is leveraging its technology platform for its own product pipeline. And for scientists seeking reagents for research use. Aug 17, 2015. Aug 13, 2015. Jul 29, 2015. Aug 17, 2015.

CONTENT

This web page had the following in the homepage, "Pfenex is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins." We viewed that the web site stated " Our initial focus is on biosimilar therapeutics and our lead product is PF582, a biosimilar to Lucentis ranibizumab." It also said " Our patented protein production platform, Pfenex Expression Technology. Pfenex is leveraging its technology platform for its own product pipeline. And for scientists seeking reagents for research use."

SEEK SUBSEQUENT BUSINESSES

Pickett Post

Sunday, April 12, 2015. William the Conqueror, First Norman King of England. Yes, you are the decedent of William the Conqueror, the First Norman King of England. That also goes for Americans of English decent as well! William was born in 1028 in Normandy, France. William was the bastard son of Robert I Duke of Normandy. He was in constant danger.

QLOCKTWO 2014

Bei Interesse bitte bei mir melden. Wir können über unseren Lieferanten auch noch weitere Edelstahlfronten bestellen. 4301; 1mm Stärke; gebürstet. Die Kosten liegen bei 40,- pro Platte ohne Versand. Im September 2014 habe ich dann die gleiche Uhr nochmals gebaut, beide Uhren laufen bis auf eine aus.

DANWOOD-DE - Hauptseite

Energie-Sparfuchs-Angebot - Effizienz-55 Häuser zu unschlagbaren Preisen - Schlau sein wie ein Fuchs und Aktionsbonus mitnehmen! Ist hier möglich. Unter diesem Motto erhalten Sie hiermit ein extrem günstiges und zukunftsorientiertes Hauskonzeptpaket als Effizienz-55-Haus als Aktionsangebot. Entscheiden Sie sich jetzt für Ihre sichere Zukunft -. Wir freuen uns auf Ihren Anruf.

Scottish Diary 2013 Frank Martins Radreise-Blog

Den bisher eingeplanten zeitlichen Puffer haben wir dringend gebraucht. Jetzt ist aber alles verpackt und wir warten auf den Checkin. Am Checkin treffen wir weitere Radler, die den easyjet Flug nach Reykjavík nehmen. Diese haben ihre Räder nur mit dicker Plastikfolie und Gewebeband eingepackt. Das hätten wir vorher wissen sollen. Heute radeln wir in die Altstadt, um einige Sehenswürdigkeiten abzuklappern.

Mogli Steven Mutschler

On 24 April 2011 by steven062010. On 7 Februar 2011 by steven062010. Am heutigen Sonntag gelang mir der Umgang mit den Darts schon etwas besser. Danach hatte ich eine sehr lange Pause, welche mir nicht zu gute gekommen ist. Spannender und erfolgreicher Kampf mit wichtigen Punkten.